Innate immunity in human embryonic stem cells: comparison with adult human endothelial cells.
Treatment of human disease with human embryonic stem cell (hESC)-derived cells is now close to reality, but little is known of their responses to physiological and pathological insult. The ability of cells to respond via activation of Toll like receptors (TLR) is critical in innate immune sensing in most tissues, but also extends to more general danger sensing, e.g. of oxidative stress, in cardiomyocytes. We used biomarker release and gene-array analysis to compare responses in hESC before and after differentiation, and to those in primary human endothelial cells. The presence of cardiomyocytes and endothelial cells was confirmed in differentiated cultures by immunostaining, FACS-sorting and, for cardiomyocytes, beating activity. Undifferentiated hESC did not respond with CXCL8 release to Gram positive or Gram negative bacteria, or a range of PAMPs (pathogen associated molecular patterns) for TLRs 1-9 (apart from flagellin, an activator of TLR5). Surprisingly, lack of TLR-dependent responses was maintained over 4 months of differentiation of hESC, in cultures which included cardiomyocytes and endothelial cells. In contrast, primary cultures of human aortic endothelial cells (HAEC) demonstrated responses to a broad range of PAMPs. Expression of downstream TLR signalling pathways was demonstrated in hESC, and IL-1beta, TNFalpha and INFgamma, which bypass the TLRs, stimulated CXCL8 release. NFkappaB pathway expression was also present in hESC and NFkappaB was able to translocate to the nucleus. Low expression levels of TLRs were detected in hESC, especially TLRs 1 and 4, explaining the lack of response of hESC to the main TLR signals. TLR5 levels were similar between differentiated hESC and HAEC, and siRNA knockdown of TLR5 abolished the response to flagellin. These findings have potential implications for survival and function of grafted hESC-derived cells.
Földes
Gábor
G
National Heart and Lung Institute, Imperial College, London, United Kingdom.
Liu
Alexander
A
Badiger
Rekha
R
Paul-Clark
Mark
M
Moreno
Laura
L
Lendvai
Zsuzsanna
Z
Wright
Jamie S
JS
Ali
Nadire N
NN
Harding
Sian E
SE
Mitchell
Jane A
JA
D000328:Adult; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics; D048430:Cell Shape / Q000187:drug effects; D002478:Cells, Cultured; D053595:Embryonic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000276:immunology; D005408:Flagellin / Q000276:immunology; D005786:Gene Expression Regulation / Q000187:drug effects; D055785:Gene Knockdown Techniques; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D016209:Interleukin-8 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D051192:Receptors, Pattern Recognition / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects / Q000276:immunology; D051193:Toll-Like Receptors / Q000235:genetics / Q000378:metabolism
C508606:CXCL8 protein, human; D016209:Interleukin-8; D008070:Lipopolysaccharides; D016328:NF-kappa B; D051192:Receptors, Pattern Recognition; D051193:Toll-Like Receptors; D005408:Flagellin
Nat Rev Immunol. 2007 May;7(5):379-90
17457344
Shock. 2007 Oct;28(4):434-40
17558348
Circulation. 2004 Nov 2;110(18):2869-74
15505089
Stem Cells Dev. 2007 Aug;16(4):615-23
17784835
Regen Med. 2008 Jan;3(1):23-31
18154460
Thromb Haemost. 2007 Aug;98(2):319-26
17721613
Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):80-9
19875721
Nat Clin Pract Cardiovasc Med. 2007 Aug;4(8):444-54
17653117
Br J Pharmacol. 2008 Feb;153(4):751-9
18193079
J Biol Chem. 2001 Feb 16;276(7):5197-203
11083876
Cardiovasc Res. 2005 Nov 1;68(2):224-34
15967420
J Clin Invest. 2006 Nov;116(11):3050-9
17053835
BMC Physiol. 2007 Jun 25;7:5
17592640
Am J Respir Crit Care Med. 2007 Mar 15;175(6):595-603
17234906
J Cardiovasc Pharmacol Ther. 2007 Dec;12(4):322-6
18172227
Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G96-G108
16179598
Hum Mol Genet. 2006 Jun 1;15(11):1894-913
16644866
Semin Immunol. 2007 Feb;19(1):3-10
17275324
J Clin Invest. 1999 Aug;104(3):271-80
10430608
Science. 2008 Apr 11;320(5873):226-30
18403709
Stem Cells. 2009 Jul;27(7):1604-15
19544467
BMB Rep. 2008 Oct 31;41(10):705-9
18959816
Semin Immunol. 2007 Feb;19(1):24-32
17275323
Biochem Biophys Res Commun. 2006 Aug 18;347(1):89-99
16814255